Conference Coverage

Cannabis for pain linked to slight risk for arrhythmia


 

FROM ESC CONGRESS 2022

Cancer, musculoskeletal, and neurologic pain

For this analysis, the researchers identified 1.8 million patients in Denmark who were diagnosed with chronic pain between 2018 and 2021.

Of those, around 5,000 patients had claimed at least one prescription of medicinal cannabis (dronabinol 29%, cannabinoids 46%, or cannabidiol 25%).

The patients had a median age of 60 years, and 63% were women.

The cannabis users had been prescribed this therapy for musculoskeletal (35%), cancer (18%), neurological (14%), or other (33%) pain, Dr. Nouhravesh said.

The researchers and Dr. Olshansky have no relevant financial disclosures.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Coffee drinking in midlife tied to heart benefits
MDedge Neurology
PRAGUE-17: LAA closure holds up against DOACs out to 4 years
MDedge Neurology
Seniors face higher risk of other medical conditions after COVID-19
MDedge Neurology
‘Substantial’ CVD risks, burden up to a year after COVID-19
MDedge Neurology
Cardiac arrest survival lower in COVID-19 inpatients
MDedge Neurology
Real-world data support safety of newer LAA device
MDedge Neurology
Even light drinking ups CV risk; harm rises along with intake
MDedge Neurology
Cutting dementia risk in atrial fibrillation: Does rhythm control strategy matter?
MDedge Neurology
Cutting dementia risk in AFib: Does rhythm control strategy matter?
MDedge Neurology
Atrial cardiopathy linked to 35% higher dementia risk
MDedge Neurology